Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

1
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (1)

Searched Name

respiratory biologic

Ranked By

Results Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2021;148:348-350. [PMID: 34174296 PMCID: PMC9022378 DOI: 10.1016/j.jaci.2021.06.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/09/2021] [Accepted: 06/16/2021] [Indexed: 11/19/2022] Abstract Collapse Key Words Aspirin-exacerbated respiratory disease IL-4Rα IL-5Rα IgE benralizumab dupilumab mepolizumab nasal polyp omalizumab respiratory biologic Collapse MESH Headings Aspirin/administration & dosage Aspirin/therapeutic use Asthma, Aspirin-Induced/drug therapy Asthma, Aspirin-Induced/immunology Biological Factors/therapeutic use Humans Collapse Grants K23 AI139352 NIAID NIH HHS R01 HL128241 NHLBI NIH HHS T32 AI007306 NIAID NIH HHS U19 AI095219 NIAID NIH HHS Collapse

Number

Citation Analysis

Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2021;148:348-350. [PMID: 34174296 PMCID: PMC9022378 DOI: 10.1016/j.jaci.2021.06.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/09/2021] [Accepted: 06/16/2021] [Indexed: 11/19/2022]